← All indications
Rhabdoid Tumor
A rare but highly lethal childhood tumor found almost exclusively in infants. Histopathologically, it resembles RHABDOMYOSARCOMA but the tumor cells are not of myogenic origin. Although it arises primarily in the kidney, it may be found in other parts of the body. The rhabdoid cytomorphology is believed to be the expression of a very primitive malignant cell. (From Holland et al., Cancer Medicine, 3d ed, p2210)
Drugs by status
Phase 3 trials (10)
Phase 2 trials (34)
- thalidomide
- ly-3023414
- atezolizumab
- olaparib
- talazoparib
- bvd-523
- irinotecan
- eflornithine
- selinexor
- erdafitinib
- nivolumab
- larotrectinib
- alisertib
- palbociclib
- panobinostat
- zarnestra
- ipilimumab
- vemurafenib
- celecoxib
- temozolomide
- bevacizumab
- tazemetostat
- topotecan
- bortezomib
- zoledronic acid
- Selpercatinib
- fenofibrate
- ivosidenib
- cytarabine
- fludeoxyglucose f-18
- +4 more
Phase 1 trials (44)
- simvastatin
- abemaciclib
- urea
- busulfan
- lenalidomide
- gemcitabine
- tacrolimus
- trametinib
- rifampin
- hydrocortisone
- idasanutlin
- Filgrastim
- ribociclib
- ro4929097
- sgt-53
- sirolimus
- mycophenolate
- sonidegib
- stem cells
- everolimus
- alemtuzumab
- Anti-thymocyte Globulin (Rabbit)
- itraconazole
- veliparib
- vorinostat
- wild-type reovirus
- attenuated measles vaccine - Edmonston strain
- her-2 car-t cells
- mesna
- fludarabine
- +14 more
Other trials (3)
Organizations
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (9)
Organization Involved with Phase 1 Indications (17)
- Pfizer
- Novartis
- Oncoceutics, Inc.
- Vyriad, Inc.
- National Institutes of Health (NIH)
- Baylor University
- Duke University
- Emory University
- University of Washington
- Mayo Clinic
- University of California, San Francisco
- University of Texas at Houston
- The Andrew McDonough B+ Foundation
- No More Kids With Cancer
- The Matthew Larson Foundation for Pediatric Brain Tumors
- CURE Childhood Cancer, Inc.
- Musella Foundation
Organization Involved with Other Experimental Indications (3)